BRAINVECTIS
Brainvectis is focused on the development of treatments that focus on neurodegenerative diseases such as Huntington’s and Alzheimer’s diseases. It researches about the restoration of brain cholesterol metabolism by increasing CYP46A1 in the patients’ brains. Brainvectis was founded by Nathalie Cartier Lacave in 2015. It is based in Fontenay-aux-Roses, France.
BRAINVECTIS
Social Links:
Industry:
Medical Medical Device Therapeutics
Founded:
2015-01-01
Address:
Fontenay-aux-roses, Ile-de-France, France
Country:
France
Website Url:
http://www.brainvectis.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
1000 K EUR
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Amazon Office 365 Mail GoDaddy DNS Pound Sterling Japanese Yen AWS Global Accelerator
Current Employees Featured
Founder
Official Site Inspections
http://www.brainvectis.com Semrush global rank: 5.13 M Semrush visits lastest month: 729
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 3.33.251.168
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Brainvectis"
Brain Vectis - 2025 Company Profile & Team - Tracxn
Brain Vectis - Developer of gene therapies for the treatment of Alzheimer's and Huntington's disease. Raised a total funding of $1.1M over 1 round from 1 investor.See details»
Brainvectis Company Profile - Office Locations, Competitors ... - Craft
See insights on Brainvectis including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
BrainVectis - Products, Competitors, Financials, Employees ...
BrainVectis develops gene therapy treatments for neurodegenerative diseases by targeting the cholesterol pathway in the brain. Use the CB Insights Platform to explore BrainVectis's full profile.See details»
BrainVectis 2025 Company Profile: Valuation, Investors ... - PitchBook
Information on acquisition, funding, cap tables, investors, and executives for BrainVectis. Use the PitchBook Platform to explore the full profile.See details»
BrainVectis SAS - Company Profile and News - Bloomberg Markets
Aug 14, 2015 Company profile page for BrainVectis SAS including stock price, company news, executives, board members, and contact informationSee details»
As Askbio acquires Brainvectis, Erganeo’s first start-up …
May 26, 2020 On 17 April, just over four and a half years after it was founded, Brainvectis, a start-up supported by Erganeo specialising in …See details»
AskBio acquires BrainVectis, a French gene therapy …
Asklepios BioPharmaceutical (AskBio) has acquired BrainVectis, a French company dedicated to the development of gene therapy for …See details»
BrainVectis SAS: Drug pipelines, Patents, Clinical trials - Synapse
Explore BrainVectis SAS with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 5 news, Disease Domain:Nervous System Diseases, Endocrinology and Metabolic …See details»
AskBio Acquires BrainVectis to Expand its Clinical Pipeline for ...
Apr 22, 2020 Research Triangle Park, N.C. and Paris, France, 22nd April 2020 / Sciad Newswire / Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus …See details»
AskBio Acquires BrainVectis to Expand its Clinical Pipeline for ...
Apr 24, 2020 About BrainVectis Founded in 2015 as a spinoff from the French National Institute for Health and Medical Research (INSERM), BrainVectis develops gene therapy treatments for …See details»
Asklepios BioPharmaceutical acquires Brainvectis - 2020-04-22 ...
Acquiring Organization: Asklepios BioPharmaceutical Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic …See details»
Brainvectis - Orphanet
Brainvectis 24 Rue Du Faubourg Saint Jacques 75014 PARIS FRANCE Phone 1: 0033 (0)1 57 27 46 99 Contact email: [email protected] Institution's website Contacts Professionals: …See details»
BrainVectis - LinkedIn
BrainVectis Biotechnology Research About us BrainVectis' aim is to develop gene therapy treatments for neurodegenerative diseases by targeting the cholesterol pathway in the brain.See details»
Brainvectis Company Information - Funding, Investors, and More
Brainvectis is a biotechnology company developing treatments for neurodegenerative diseases through restoring cholesterol metabolism in the brain.See details»
Brainvectis Therapeutics - Drug pipelines, Patents, Clinical trials ...
Explore Brainvectis Therapeutics with its drug pipeline, therapeutic area, technology platform, .See details»
Brainvectis: startup Médical à Paris | Annuaire Start-Up France
Brainvectis est une startup Médical à Paris qui a réalisé 1 levée de fonds (1 M€). Découvrez la présentation de l'entreprise, les infos légales et financières ainsi que d'autres startups …See details»
Brainvectis Headquarters and Office Locations - Craft
Brainvectis is headquartered in Paris, Hôpital Pitié, 47 Boulevard de l'Hôpital, France, and has 1 office location.See details»
AskBio Acquires BrainVectis - American Pharmaceutical Review
Apr 23, 2020 Asklepios has acquired BrainVectis, a Paris-based gene therapy company and French National Institute for Health and Medical Research (INSERM) spin-out with expertise …See details»
BrainVectis company information, funding & investors | Dealroom.co
BrainVectis, developing gene therapy treatments for neurodegenerative diseases by targeting the cholesterol pathway in the brain. Here you'll find information about their funding, investors and …See details»
AskBio Takes Over BrainVectis to Treat Alzheimer’s and Huntington’s
Apr 28, 2020 The Paris-based BrainVectis, a biotech developing gene therapies for Huntington’s disease and Alzheimer’s disease, has been acquired by the US clinical-stage gene therapy …See details»